Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106465 | 0.81 | GAA (0.34) | MAPTALDH1A1GAAALOX12PRKDC | |
| SCHEMBL1106456 | 0.81 | MAPT (0.33) | MAPT | |
| SCHEMBL9200910 | 0.77 | — | — | |
| SCHEMBL20907898 | 0.76 | ALDH1A1 (0.47) | MAPTALDH1A1GAAALOX12PRKDC | |
| SCHEMBL25081764 | 0.75 | PIK3R1 (0.31) | PIK3R1PIK3CA | |
| SCHEMBL105138 | 0.73 | — | — | |
| SCHEMBL25081776 | 0.72 | — | — | |
| SCHEMBL1106503 | 0.71 | CHRM2 (0.47) | MAPTALDH1A1PIK3CDCA12CA1 | |
| Ammonia Solution, Strong SCHEMBL28290304 | 0.71 | LMNA (0.48) | MAPTALDH1A1PKMKMT2APIK3CD | |
| SCHEMBL1149596 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2023020519-A1 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-23 | — | — | WO | disclosed |
| US-20230039712-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-02-09 | — | — | US | disclosed |
| US-20230000847-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | DRAIG THERAPEUTICS LTD (GB) | 2023-01-05 | — | — | US | disclosed |
| US-11298345-B2 | Compounds that modulates AMPA receptor function | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-04-12 | — | — | US | disclosed |
| US-20210113539-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | DRAIG THERAPEUTICS LTD (GB) | 2021-04-22 | — | — | US | disclosed |
| US-20200354346-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2020-11-12 | — | — | US | disclosed |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110172205-A1 | MONOCYCLIC AMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172205-A1 | MONOCYCLIC AMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000847-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | GRIN1, GRM1, GRIN2A | MAPT 1655/4885ALDH1A1 800/4885GAA 3282/4885 |
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | MAPT 3722/4885ALDH1A1 974/4885GAA 511/4885 |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAPT 2476/4885ALDH1A1 2580/4885GAA 1757/4885 |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | MAPT 2476/4885ALDH1A1 2580/4885GAA 1757/4885 |
| US-20210113539-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | GRIN1, GRM1, GRIN2A | MAPT 1655/4885ALDH1A1 800/4885GAA 3282/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | MAPT 89/4885ALDH1A1 4157/4885GAA 1897/4885 |
| US-20230039712-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | MAPT 817/4885ALDH1A1 2271/4885GAA 339/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | MAPT 3722/4885ALDH1A1 974/4885GAA 511/4885 |
| US-11298345-B2 | Compounds that modulates AMPA receptor function | GRIN1, GRM1, GRIN2A | MAPT 1655/4885ALDH1A1 800/4885GAA 3282/4885 |
| US-20110172205-A1 | MONOCYCLIC AMIDE CGRP RECEPTOR ANTAGONISTS | EDNRB, CCKBR, EDNRA | MAPT 2841/4885ALDH1A1 3169/4885GAA 2972/4885 |
| US-20200354346-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | MAPT 1127/4885ALDH1A1 2874/4885GAA 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.